Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  American Journal of Pathology

• Publication date

  2008-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2353/ajpath.2008.080478PMID 18772343PMCID PMC2543081
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protocols for Neural Cell Culture

  2010cited by this paper
• FTY720 modulates human oligodendrocyte progenitor process extension and survival

  2008influential reference
• WAVE1 and Regulation of Actin Nucleation in Myelination

  2007cited by this paper
• Simvastatin regulates oligodendroglial process dynamics and survival

  2007cited by this paper
• The Immunopathology of Multiple Sclerosis: An Overview

  2007influential reference
• Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

  2007cited by this paper
• LPA4/GPR23 Is a Lysophosphatidic Acid (LPA) Receptor Utilizing Gs-, Gq/Gi-mediated Calcium Signaling and G12/13-mediated Rho Activation*

  2007cited by this paper
• Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells

  2007cited by this paper
• The Immunomodulator FTY720 Has a Direct Cytoprotective Effect in Oligodendrocyte Progenitors

  2007cited by this paper
• Activation of sphingosine‐1‐phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration

  2007cited by this paper
• Wrapping it up: the cell biology of myelination.

  2007cited by this paper
• Emerging medicinal roles for lysophospholipid signaling.

  2006cited by this paper
• Oral fingolimod (FTY720) for relapsing multiple sclerosis.

  2006cited by this paper
• Neuronal responses to myelin are mediated by rho kinase

  2006influential reference
• Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: II. Effect of FTY720 and FTY720-phosphate on host-versus-graft and graft-versus-host reaction in mice.

  2005cited by this paper
• TLR Signaling Tailors Innate Immune Responses in Human Microglia and Astrocytes1

  2005cited by this paper
• Edg8/S1P5: An Oligodendroglial Receptor with Dual Function on Process Retraction and Cell Survival

  2005influential reference
• Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

  2005cited by this paper
• Sphingosine 1-Phosphate Analogs as Receptor Antagonists*

  2005cited by this paper
• The Sphingosine‐1‐Phosphate Receptor Agonist FTY720 Modulates Dendritic Cell Trafficking In Vivo

  2005cited by this paper
• The Sphingosine 1-Phosphate Receptor Agonist FTY720 Differentially Affects the Sequestration of CD4+/CD25+ T-Regulatory Cells and Enhances Their Functional Activity

  2005cited by this paper
• Mechanisms of axon ensheathment and myelin growth

  2005cited by this paper
• Characterization of lysophosphatidic acid and sphingosine‐1‐phosphate‐mediated signal transduction in rat cortical oligodendrocytes

  2004influential reference
• Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

  2004cited by this paper
• The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors

  2004cited by this paper
• Structural and functional characteristics of S1P receptors

  2004cited by this paper
• Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension

  2004cited by this paper
• Culture and cryopreservation of adult human oligodendrocytes and astrocytes

  2004cited by this paper
• Resistance of human adult oligodendrocytes to AMPA/kainate receptor-mediated glutamate injury.

  2004cited by this paper
• Regulation of immunity by lysosphingolipids and their G protein-coupled receptors.

  2004cited by this paper
• Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

  2004cited by this paper
• Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation.

  2003cited by this paper
• Lysophosphatidic acid induces process retraction in CG‐4 line oligodendrocytes and oligodendrocyte precursor cells but not in differentiated oligodendrocytes

  2003cited by this paper
• Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases*

  2003influential reference
• Regulated and constitutive activation of specific signalling pathways by the human S1P5 receptor

  2003cited by this paper
• Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS.

  2003cited by this paper
• Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists

  2002cited by this paper
• Comparative analysis of human and rat S1P(5) (edg8): differential expression profiles and sensitivities to antagonists.

  2002cited by this paper
• Why does remyelination fail in multiple sclerosis?

  2002cited by this paper
• Cutting Edge: Suppression of T Cell Chemotaxis by Sphingosine 1-Phosphate1

  2002cited by this paper
• EDG Receptors as a Therapeutic Target in the Nervous System

  2000cited by this paper
• Differential Pharmacological Properties and Signal Transduction of the Sphingosine 1-Phosphate Receptors EDG-1, EDG-3, and EDG-5*

  1999cited by this paper
• Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1.

  1999cited by this paper
• Endogenous progenitors remyelinate demyelinated axons in the adult CNS.

  1997cited by this paper
• Culture of Glial Cells from Human Brain Biopsies

  1997cited by this paper
• Multiple Sclerosis: Fas Signaling in Oligodendrocyte Cell Death

  1996cited by this paper
• Turnover of myelin proteins in mouse brain in vivo.

  1977cited by this paper
• Metabolic studies on myelin. Evidence for a precursor role of a myelin subfraction.

  1974cited by this paper
• The turnover of myelin in the adult rat.

  1968cited by this paper

• Design and Synthesis of Novel PET Radiotracers for Imaging Sphingosine-1-Phosphate Receptor 5 (S1PR5) in the Brain.

  2025cites this paper
• Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.

  2023cites this paper
• Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5

  2022influential citation
• Treatment of Multiple Sclerosis

  2022cites this paper
• Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5

  2021influential citation
• Novel Potent Selective Orally Active S1P5 Receptor Antagonists.

  2021cites this paper
• The emerging role of FTY720 as a sphingosine 1‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms

  2021cites this paper
• A2B Adenosine Receptors and Sphingosine 1-Phosphate Signaling Cross-Talk in Oligodendrogliogenesis

  2021cites this paper
• Lessons from S1P receptor targeting in multiple sclerosis.

  2021cites this paper
• The role of Sphingolipids in myelination and myelin stability and their involvement in childhood and adult demyelinating disorders

  2020cites this paper
• Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process

  2020cites this paper
• Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation

  2020cites this paper
• Species differences in immune‐mediated CNS tissue injury and repair: A (neuro)inflammatory topic

  2019cites this paper
• Long noncoding RNAs APOA1-AS, IFNG-AS1, RMRP and their related biomolecules in Egyptian patients with relapsing-remitting multiple sclerosis: Relation to disease activity and patient disability

  2019cites this paper
• Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.

  2019cites this paper
• Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model.

  2019cites this paper
• Mécanismes d’actions des biothérapies dans la SEP

  2019cites this paper
• Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables

  2018cites this paper
• Roles of lysophosphatidic acid and sphingosine-1-phosphate in stem cell biology.

  2018cites this paper
• Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis

  2018cites this paper
• Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis.

  2017cites this paper
• Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.

  2017cites this paper
• Acid sphingomyelinase deficiency blocks chronic experimental autoimmune encephalomyelitis and improves myelin repair

  2017cites this paper
• [Fingolimod in Spain: usual clinical practice].

  2016cites this paper
• Sphingosine kinase inhibition ameliorates chronic hypoperfusion-induced white matter lesions.

  2016cites this paper
• S1P1 deletion in oligodendroglial lineage cells: Effect on differentiation and myelination

  2016cites this paper
• Cell Injury , Repair , Aging and Apoptosis Fingolimod ( FTY 720 ) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices

  2016cites this paper
• Fingolimod Prevents Blood-Brain Barrier Disruption Induced by the Sera from Patients with Multiple Sclerosis

  2015cites this paper
• Sphingosine 1-phosphate signaling at the blood-brain barrier.

  2015cites this paper
• Fingolimod does not enhance cerebellar remyelination in the cuprizone model.

  2015cites this paper
• The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

  2015cites this paper
• The sphingosine 1‐phosphate receptor agonist FTY720 is neuroprotective after cuprizone‐induced CNS demyelination

  2015cites this paper
• Newer Agents in the Treatment of Multiple Sclerosis

  2015cites this paper
• Sphingosine-1-phosphate receptor antagonism enhances proliferation and migration of engrafted neural progenitor cells in a model of viral-induced demyelination.

  2015cites this paper
• From demyelination to remyelination: The road toward therapies for spinal cord injury

  2015influential citation
• The role of Lysophosphatidic Acid in Traumatic Brain Injury outcomes

  2015cites this paper
• Galactosylsphingosine (psychosine)-induced demyelination is attenuated by sphingosine 1-phosphate signalling

  2015influential citation
• Neurobehavioral consequences of small molecule-drug immunosuppression.

  2015cites this paper
• Immunohistochemical detection of sphingosine‐1‐phosphate receptor 1 and 5 in human multiple sclerosis lesions

  2014cites this paper
• Sphingosine-1-Phosphate Signaling in Immunology and Infectious Diseases

  2014cites this paper
• ASP4058, a Novel Agonist for Sphingosine 1-Phosphate Receptors 1 and 5, Ameliorates Rodent Experimental Autoimmune Encephalomyelitis with a Favorable Safety Profile

  2014cites this paper
• Efectos del fingolimod en el sistema nervioso central

  2014cites this paper
• Central effects of fingolimod.

  2014cites this paper
• Fingolimod for the treatment of neurological diseases—state of play and future perspectives

  2014cites this paper
• Heterogeneity of oligodendrocyte progenitor cells in adult human brain

  2014cites this paper
• Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis

  2014cites this paper
• Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis

  2014cites this paper
• Mechanisms of action of fingolimod in multiple sclerosis

  2014cites this paper
• Sphingosine-1 phosphate and central nervous system.

  2014cites this paper
• Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice

  2013cites this paper
• Intravenous Gammaglobulin Inhibits Encephalitogenic Potential of Pathogenic T Cells and Interferes with their Trafficking to the Central Nervous System, Implicating Sphingosine-1 Phosphate Receptor 1–Mammalian Target of Rapamycin Axis

  2013cites this paper
• Novel S1P1 receptor agonists--part 1: From pyrazoles to thiophenes.

  2013cites this paper
• Myelin Recovery in Multiple Sclerosis: The Challenge of Remyelination

  2013cites this paper
• Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

  2013cites this paper
• Lysophospholipids and their receptors in the central nervous system.

  2013cites this paper
• Effects of Current Medical Therapies on Reparative and Neuroprotective Functions in Multiple Sclerosis

  2013cites this paper
• The role of sphingosine 1-phosphate receptors in the treatment of demyelinating diseases

  2013cites this paper
• Mammalian Target of Rapamycin Axis - phingosine-1 Phosphate Receptor 1 the Central Nervous System, Implicating S Cells and Interferes with their Trafficking to Encephalitogenic Potential of Pathogenic T Intravenous Gammaglobulin Inhibits

  2013cites this paper
• Pharmacological Modulation of Peripheral T and B Lymphocytes by a Selective Sphingosine 1‐Phosphate Receptor‐1 Modulator

  2012cites this paper
• Signaling and Regulatory Functions of Bioactive Sphingolipids as Therapeutic Targets in Multiple Sclerosis

  2012cites this paper
• Remyelination Therapy for Multiple Sclerosis

  2012cites this paper
• FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination

  2012cites this paper
• [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].

  2012cites this paper
• [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].

  2012cites this paper
• [Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval].

  2012cites this paper
• Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.

  2012cites this paper
• Fingolimod-Compassionate-use-Programm

  2012cites this paper
• Assessment of sphingosine-1-phosphate receptor expression and associated intracellular signaling cascades in primary cells of the human central nervous system.

  2012cites this paper
• Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.

  2012cites this paper
• Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

  2012cites this paper
• S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures

  2012influential citation
• Fingolimod modulates microglial activation to augment markers of remyelination

  2011cites this paper
• Emerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence

  2011cites this paper
• Synthetic sphingosine 1-phosphate receptor modulators--opportunities and potential pitfalls.

  2011cites this paper
• Neurobiological effects of sphingosine 1‐phosphate receptor modulation in the cuprizone model

  2011cites this paper
• The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators

  2011cites this paper
• The effect of FTY720 in the Theiler's virus model of multiple sclerosis.

  2011cites this paper
• Involvement of the sphingosine 1-phosphate receptor 3 in neuro-inflammation

  2011cites this paper
• Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions

  2011cites this paper
• [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].

  2011cites this paper
• Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

  2011cites this paper
• Differential responses of human microglia and blood-derived myeloid cells to FTY720.

  2011cites this paper
• Emerging oral disease-modifying therapies

  2011cites this paper
• Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

  2011cites this paper
• Cells of the oligodendroglial lineage, myelination, and remyelination.

  2011cites this paper
• Roles for lysophospholipid S1P receptors in multiple sclerosis

  2011influential citation
• Fingolimod is a potential novel therapy for multiple sclerosis

  2010cites this paper
• Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.

  2010cites this paper
• Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

  2010influential citation
• Orales Fingolimod bei Multipler Sklerose

  2010cites this paper
• Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists

  2010cites this paper
• Fingolimod for relapsing multiple sclerosis: an update

  2010cites this paper
• Einfluss von FTY720, S1P und Estrogen auf die Tumorpromotion

  2010cites this paper
• The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.

  2010cites this paper
• Sphingosine 1‐phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions

  2010cites this paper
• Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (Fingolimod) in multiple sclerosis

  2010cites this paper
• 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.

  2010cites this paper
• Phosphorylation of the Immunomodulator FTY720 Inhibits Programmed Cell Death of Fibroblasts Via the S1P3 Receptor Subtype and Bcl-2 Activation

  2010cites this paper
• Sphingosine-1-phosphate and oligodendrocytes: from cell development to the treatment of multiple sclerosis.

  2010cites this paper
• S1P(1) receptor agonists: Assessment of selectivity and current clinical activity.

  2010cites this paper